JP4397591B2 - 天然痘ワクチン - Google Patents
天然痘ワクチン Download PDFInfo
- Publication number
- JP4397591B2 JP4397591B2 JP2002582984A JP2002582984A JP4397591B2 JP 4397591 B2 JP4397591 B2 JP 4397591B2 JP 2002582984 A JP2002582984 A JP 2002582984A JP 2002582984 A JP2002582984 A JP 2002582984A JP 4397591 B2 JP4397591 B2 JP 4397591B2
- Authority
- JP
- Japan
- Prior art keywords
- vaccinia virus
- pharmaceutical composition
- strain
- virus
- acam1000
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940083538 smallpox vaccine Drugs 0.000 title description 3
- 241000700618 Vaccinia virus Species 0.000 claims description 45
- 241000700605 Viruses Species 0.000 claims description 29
- 238000004113 cell culture Methods 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 230000002238 attenuated effect Effects 0.000 claims description 12
- 231100000419 toxicity Toxicity 0.000 claims description 11
- 230000001988 toxicity Effects 0.000 claims description 11
- 230000001681 protective effect Effects 0.000 claims description 9
- 108091008146 restriction endonucleases Proteins 0.000 claims description 8
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 5
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000005847 immunogenicity Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 210000004748 cultured cell Anatomy 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 description 57
- 238000000034 method Methods 0.000 description 22
- 241000700647 Variola virus Species 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 17
- 206010046865 Vaccinia virus infection Diseases 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 208000007089 vaccinia Diseases 0.000 description 13
- 238000002255 vaccination Methods 0.000 description 12
- 229940125575 vaccine candidate Drugs 0.000 description 10
- 206010029350 Neurotoxicity Diseases 0.000 description 8
- 206010044221 Toxic encephalopathy Diseases 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 231100000228 neurotoxicity Toxicity 0.000 description 8
- 230000007135 neurotoxicity Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 231100000111 LD50 Toxicity 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 244000309466 calf Species 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008029 eradication Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000700629 Orthopoxvirus Species 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000700626 Cowpox virus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010059516 Skin toxicity Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000004720 cerebrum Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 201000003740 cowpox Diseases 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000003186 pharmaceutical solution Substances 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 231100000438 skin toxicity Toxicity 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 206010037083 Prurigo Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 230000005156 neurotropism Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012770 revaccination Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 201000006266 variola major Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24161—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/840,751 US6723325B1 (en) | 2001-04-23 | 2001-04-23 | Smallpox vaccine |
| PCT/US2002/012616 WO2002085411A1 (en) | 2001-04-23 | 2002-04-23 | Smallpox vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005503126A JP2005503126A (ja) | 2005-02-03 |
| JP2005503126A5 JP2005503126A5 (https=) | 2006-01-12 |
| JP4397591B2 true JP4397591B2 (ja) | 2010-01-13 |
Family
ID=25283120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002582984A Expired - Fee Related JP4397591B2 (ja) | 2001-04-23 | 2002-04-23 | 天然痘ワクチン |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6723325B1 (https=) |
| EP (1) | EP1381389B1 (https=) |
| JP (1) | JP4397591B2 (https=) |
| KR (1) | KR20040063083A (https=) |
| CN (1) | CN1527722A (https=) |
| AU (1) | AU2002258910B2 (https=) |
| BR (1) | BR0209145A (https=) |
| CA (1) | CA2444747C (https=) |
| CZ (1) | CZ305819B6 (https=) |
| EA (1) | EA007656B1 (https=) |
| ES (1) | ES2546612T3 (https=) |
| HU (1) | HU228401B1 (https=) |
| IL (2) | IL158549A0 (https=) |
| MA (1) | MA26270A1 (https=) |
| MX (1) | MXPA03009711A (https=) |
| NZ (1) | NZ529265A (https=) |
| PL (1) | PL212117B1 (https=) |
| WO (1) | WO2002085411A1 (https=) |
| ZA (1) | ZA200309084B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645456B2 (en) * | 2001-04-23 | 2010-01-12 | Sanofi Pasteur Biologics Co. | Vaccinia virus strains |
| US6723325B1 (en) * | 2001-04-23 | 2004-04-20 | Acambis, Inc. | Smallpox vaccine |
| US20090269365A1 (en) * | 2005-04-20 | 2009-10-29 | University Of Washington | Immunogenic vaccinia peptides and methods of using same |
| MX2009004862A (es) | 2006-11-07 | 2009-07-17 | Sanofi Pasteur Biologics Co | Estabilizacion de vacunas por liofilizacion. |
| KR100859345B1 (ko) * | 2006-12-12 | 2008-09-19 | 씨제이제일제당 (주) | 세포배양에 의해 두창 백신을 생산하는 방법 및 그에 의해생산된 두창 백신 |
| ES2733211T3 (es) * | 2011-04-15 | 2019-11-28 | Genelux Corp | Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas |
| RU2496149C1 (ru) * | 2012-06-19 | 2013-10-20 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") | Способ оценки противооспенной активности лечебно-профилактических препаратов |
| JP2019535311A (ja) | 2016-11-02 | 2019-12-12 | デイビッド エバンス， | 合成キメラポックスウイルス |
| EP3788142A4 (en) | 2018-05-02 | 2022-04-27 | Tonix Pharma Holdings Limited | SYNTHETIC CHIMERIC VACCINE VIRUS |
| US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
| CA3116192C (en) | 2018-11-06 | 2025-09-23 | Calidi Biotherapeutics (Nevada), Inc. | IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY |
| WO2025184411A1 (en) | 2024-02-27 | 2025-09-04 | Calidi Biotherapeutics (Nevada), Inc. | Serum-resistant eev viruses and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4315914A (en) * | 1980-04-04 | 1982-02-16 | Seiji Arakawa | Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof |
| JPS60202827A (ja) | 1984-03-28 | 1985-10-14 | Chibaken | 弱毒痘そうワクチン株 |
| US5614193A (en) * | 1991-11-14 | 1997-03-25 | The United States Of America As Represented By The Secretary Of The Army | Hantavirus vaccine |
| US5656465A (en) * | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
| US6723325B1 (en) | 2001-04-23 | 2004-04-20 | Acambis, Inc. | Smallpox vaccine |
-
2001
- 2001-04-23 US US09/840,751 patent/US6723325B1/en not_active Expired - Lifetime
-
2002
- 2002-04-23 PL PL373958A patent/PL212117B1/pl unknown
- 2002-04-23 KR KR10-2003-7013866A patent/KR20040063083A/ko not_active Ceased
- 2002-04-23 HU HU0303878A patent/HU228401B1/hu unknown
- 2002-04-23 BR BR0209145-3A patent/BR0209145A/pt active Search and Examination
- 2002-04-23 CN CNA028126335A patent/CN1527722A/zh active Pending
- 2002-04-23 EP EP02728888.5A patent/EP1381389B1/en not_active Expired - Lifetime
- 2002-04-23 AU AU2002258910A patent/AU2002258910B2/en not_active Ceased
- 2002-04-23 EA EA200301151A patent/EA007656B1/ru not_active IP Right Cessation
- 2002-04-23 IL IL15854902A patent/IL158549A0/xx unknown
- 2002-04-23 JP JP2002582984A patent/JP4397591B2/ja not_active Expired - Fee Related
- 2002-04-23 ES ES02728888.5T patent/ES2546612T3/es not_active Expired - Lifetime
- 2002-04-23 WO PCT/US2002/012616 patent/WO2002085411A1/en not_active Ceased
- 2002-04-23 CZ CZ2003-3184A patent/CZ305819B6/cs not_active IP Right Cessation
- 2002-04-23 MX MXPA03009711A patent/MXPA03009711A/es active IP Right Grant
- 2002-04-23 NZ NZ529265A patent/NZ529265A/en not_active IP Right Cessation
- 2002-04-23 CA CA2444747A patent/CA2444747C/en not_active Expired - Lifetime
-
2003
- 2003-05-27 US US10/445,671 patent/US7115270B2/en not_active Expired - Lifetime
- 2003-10-22 IL IL158549A patent/IL158549A/en unknown
- 2003-11-17 MA MA27401A patent/MA26270A1/fr unknown
- 2003-11-21 ZA ZA2003/09084A patent/ZA200309084B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7115270B2 (en) | 2006-10-03 |
| EP1381389A1 (en) | 2004-01-21 |
| HUP0303878A3 (en) | 2010-01-28 |
| ES2546612T3 (es) | 2015-09-25 |
| KR20040063083A (ko) | 2004-07-12 |
| WO2002085411A1 (en) | 2002-10-31 |
| MXPA03009711A (es) | 2005-03-07 |
| US6723325B1 (en) | 2004-04-20 |
| PL373958A1 (en) | 2005-09-19 |
| AU2002258910B2 (en) | 2007-10-25 |
| EP1381389B1 (en) | 2015-08-26 |
| CA2444747A1 (en) | 2002-10-31 |
| US20060153873A1 (en) | 2006-07-13 |
| CZ20033184A3 (cs) | 2004-04-14 |
| ZA200309084B (en) | 2005-01-26 |
| HU228401B1 (en) | 2013-03-28 |
| CA2444747C (en) | 2018-04-17 |
| PL212117B1 (pl) | 2012-08-31 |
| NZ529265A (en) | 2006-04-28 |
| HK1062804A1 (zh) | 2004-11-26 |
| EA007656B1 (ru) | 2006-12-29 |
| EA200301151A1 (ru) | 2004-10-28 |
| IL158549A (en) | 2009-07-20 |
| MA26270A1 (fr) | 2004-09-01 |
| BR0209145A (pt) | 2005-04-19 |
| IL158549A0 (en) | 2004-05-12 |
| HUP0303878A2 (hu) | 2004-03-01 |
| CN1527722A (zh) | 2004-09-08 |
| EP1381389A4 (en) | 2004-07-28 |
| JP2005503126A (ja) | 2005-02-03 |
| CZ305819B6 (cs) | 2016-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003239805B2 (en) | Modified vaccinia virus ankara for the vaccination of neonates | |
| US20090324548A1 (en) | Vaccinia Virus Strains | |
| JP4397591B2 (ja) | 天然痘ワクチン | |
| JP5988463B2 (ja) | Ｍｖａによる病原体からの即時保護 | |
| AU2002258910A1 (en) | Smallpox vaccine | |
| HK1062804B (en) | Smallpox vaccine | |
| Handley et al. | Orthopoxvirus vaccines and vaccination | |
| HK1078777B (en) | Modified vaccinia virus ankara for the vaccination of neonates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050412 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050419 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051117 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080414 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080711 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080718 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080812 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080819 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080912 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080922 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081014 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090209 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090511 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090513 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090715 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090721 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090826 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090828 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090925 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091021 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121030 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4397591 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131030 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |